EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
The hospital was recognised as a Winner (Medium) in the category of Best Academic Institution (Government/Private)
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Subscribe To Our Newsletter & Stay Updated
